<b>8</b> ?				
Form PTO-149 JUN 1 7 2005 U.S. DEPARTMENT OF COMMERCE (Rev. ) PATENT AND TRADEMARK OFFICE				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANTS Harold M. Bates			
(Use several sheets if necessary)	FILING DATE February 12, 2004	GROUP		

### **U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	U.S. Patent Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

#### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
			1				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

June 8, 2005 International Search Report and Written Opinion for PCT/US05/02327.								
Armitage & Colton (editors), Encyclopedia of Biostatistics, volume 5, pages 3628-3629 and 3838-3842 (1998).								
01/22/2007								

not considered. Include copy of this form with next communication to applicant.

	PATI ORMATION DISCLOSU	NT OF COMMERCE ADEMARK OFFICE IENT							
III SEP O 5 Vanna	(Use several sheets if			APPLICANT Harold M. Bates					
PARTE TO SERVICE TO SE	<b>X</b>			FILING DATE Februar	y 12, 2004	GROU	P: <b>1</b> 646		
AP FILL			U.S. PATENT D	OCUMENTS .			/		
Examiner Initial	Document Number	Date		Name	Class	Subclass	Filing Date If Appropriat	e	
	·		<u> </u>						
			FO	REIGN PATENT D	OCUME!	NTS			
	Document Number	Date		Country	Class	Subclass	Translati	ion	
			$\longrightarrow$	<u>/</u>	<u> </u>				
	OTHE	D DOCUM	DAVIDS (I. I. II. I						
	Griffin ME, N "Autoantiboo Fatty Acid C	McInerney dies to Oxid omposition	O, Fraser A, Joh dized Low Densi n in Diabetes." <i>D</i>	uthor, Title, Date, Pertinonation AH, Collins PE ty Lipoprotein: the Foliabetic Medicine	3, Owens Relationsh 997), volu	D, Tomkin ip to Low D me 14, pag	ensity Lipopies 741-747.		
	American H Palinski W, Monoclonal	art Journa Horkko S, I Autoantibo	al (1992), volume Miller E, Steinbre odies to Epitopes	e 123, pages 285-29 echer UP, Powell Ho of Oxidized Lipopro (1996), volume 98,	00. C, Curths oteins fro	LK, Witztur Q Apolipopr	n JL. "Cloni	ng of	
	C, Marks JD Evolution of	. "Isolation the Compl	n of Picomolar Ai ementary Detern	all KW, Merritt H, Yi ffinity Anti-c-erbB-2 nining Regions in th lume 263, pages 55	Single-ch e Center	ain Fv by M	lolecular		
				nteractions: Their Q comatography (1989				Jse	
EXAMINER	/David V			DATE CONSIDERED		1/22/200			
Examiner: Initial i	f citation considered, who clude copy of this form w	ther or not ci	tation is in conforma nunication to applica	nce with MPER609; Drav	v line throug	h citation if no	ot in conformat	e and	

Form PTO-1449 (Rev. )			T OF COMMERCE DEMARK OFFICE				i	APPLICATION NO.: 10/777,543		
	ORMATION DISCLOSUI  BY APPLICAN  (Use several sheets if i	<b>VT</b>	ENT	C1304					/	
OTRE		••		APPLICANT Harold M. Bates						
AUG 29 M				FILING DATE February 12, 2004 GROUP: 1646						
THE TOWN OF W	art Control of the Co	1	U.S. PATENT D	OCUN	MENTS					
Examiner Initial	Document Number	Date		Name		Class	Sub	class	Filing Date If Appropria	te
	+					/	_			
	+					$\overline{}$				
						/				
· .			<b>\</b>							
					/					
				$\angle$						
			$\bot$							
		ı .	FO	KEIG	N PATENT DO	CUMENT	S	ı I		<u>1</u>
	Document Number	Date	c	Country		Class	Sub	class	Translat	ion
	4-173096	6/1992	JA	PAN					English Abstract	
				-						
						$\downarrow$				
<u> </u>				<del></del>		-				
	OFHER	DOCUME	ENTS (Including A	uthor, T	itle, Date, Pertiner	it Pages, Etc.)	_			
		<u></u>					_	$\overline{}$	<del></del>	
								1		
EXAMINER	/ / / / / / / / / / / / / / / / / / / /	1.5 **	· / · · · · · · · · · · · · · · · · · ·	D. T. C.	CONCIDENCE	01	75	2/200		
Examiner: Injual i	/Day f citation considered, whet clude wpy of this form wit	id Venc: ther or not cita b next comm	ation is in conformar	nce with	ONSIDERED  MPEP 609; Drav			2/200 ition if no		nce and
	we or and total with	- next commi	to approun					······································		
						•				

RS1336148

Form PTO-1449 Rev. ) INFO		NT AND TRAE RE STATEME NT	OF COMMERCE DEMARK OFFICE NT	ATTY. DOCKET NO C15043/174944	<b>)</b> .:	APPLIC 10/777,5	ATION NO.:			
2 6 2016				APPLICANT Harold M. Bates						
MAI	·			FILING DATE February 12, 2004 GROUP: 646						
FRADON		U	J.S. PATENT D	OCUMENTS		/				
Examiner Initial	Document Number	Date		Name	Class	Subolass	Filing Date If Appropriate			
				·	-	/				
					/					
				/						
			· \	-						
			$\overline{}$							
			FO	REIGN PATENT	DOCUME	NTS				
	Document Number	Date		Country	Class	Subclass	Translation			
			/	$\overline{}$						
					$\overline{}$					
	OTHER	DOCUME	NTS (Including A	uthor, Title, Date, Per	tinent Pages,	Etc.)	<u> </u>			
	T			brochure (photoco		<del>}</del>	ember 2004.			
	Johnston N, J Joronary Arte 1; 97(5): 640-	ry Disease B	y The Use Of No	gbahn A, Wallentin ew Lipid And Lipop	L. *Improverotein Bioma	d Identification	on Of Patents With Cardiol. 2006 Mar			
	Johnston N, J	emberg T, La	agerqvist B, Siegatients With Uns	bahn A, Wallentin table Coronary Art	L. *Oxidized ery Disease,	Low-Densit	Lipoprotein As A			
							. \			
EXAMINER	/Day:	d Venci/	/T	DATE CONSIDERED	\	1/22/200				

Form PTO-1449 (NRev. )	PATENT AND TRADEMARK OFFI  PATENT AND TRADEMARK								
( NOV )	0 2005 "	•		APPLICANT Harold M. Bates					
A THE SEAL OF THE	A CONTRACTOR OF THE PROPERTY O			FILING DATE February 12, 2004 GROUP: 1646					
		· · · · · · · · · · · · · · · · · · ·	U.S. PATENT D	OCUMENTS		7			
Examiner Initial	Document Number	Date		Name	Class	Subclass	Filing Date If Appropriate		
	<del>                                     </del>								
	_								
	<u> </u>			-/-				<del></del>	
			$\longrightarrow$				,		
		<u> </u>	FO	REIGN PATENT D	OCUMEN	TS	1	-	
	Document Number	Date		Country	Subclass	Translation	n		
				$\overline{}$					
				uthor, Title, Date, Pertin		<del>\</del>			
	esari M, Krit Newman AB,	chevsky SB, Pahor M. "L	, Nicklas BJ, Peni ipoprotein peroxi	eart Disease," Acta C ninx BW, Holvoet P, I dation and mobility lir 2005 Oct 10; 165(18)	Coh-Banerje	e P, Summ	nings SR, Harris		
	strong predict	or for acute	coronary heart di	newel H, Koenig W. sease events in appa 2; 112(5): 651-657 (E	rently healtl	hy, middle-a			
XAMU ER	/David	Venci/		DATE CONSIDERED	0:	1/22/200	7		
xapiiner: Initial if	citation considered, whe	ther or not cite	ation is in conforma	ce with MPEP 609; Drav	<del></del>			<b>Prod</b>	

Form PTO-1 (Rt v. )	449		DEPARTMENT OF								
di	r BRA	TION DISCLO	OSURE STATEM	IENT	APPLICANT Harold M. Bates						
JUH 1	8 2001	se several sheet	s if necessary)		FILING DATE GROUP						
To Ruo	- Nat Q	<u> </u>			February 12, 2004	OV D. CO. VIDO		t Assigned			
Examiner Initial	Cite No.	U.S. Petent Document	Date		U.S. PATENT DO	Class	Subclass	Filing Da			
	110.	Number	Date		Name	Class	Succiass	11 Арргор			
		· \				/	1				
_		<del>-</del>	<del>\                                    </del>								
·			+			+			<del></del>		
						<u>/                                    </u>					
				<u> </u>				-			
	·		1	FO	REIGN PATENT I	DOCUMEN	NTS	<u> </u>			
		Document Number	Date		Country	Class	Subclass	Tran	slation		
				X				Yes	No		
					<del>\</del>						
		,		/		•					
				/							
					$\overline{}$						
	L	ОТІ	IER DOCUMEN	TS (Including A	uthor, Title, Date, Pertir	ent Pages, Etc	_ <del> </del> c.)				
		Holvoet P, Krito Syndrome, Circu	hevsky SB, Tracy RJ	P, Mertens A, R L, And Risk of N	ubin SM, Butler J, God Ayocardial Infarction I abetes. 2004; 53(4): 19	odpaster B, H n Well-Func	arris TB. "Th	e Metabolio People In	The		
		Sigurdardottir V Factors of The N 2002; 257(5): 44	letabolic Syndrome	e J. "Circulating And LDL Size i	Oxidized Low-Densit n Clinically Healthy 58	y Lipoprotei B-Year-Old M	(LDL) Is Ass 1et (AIR Stud	sociated Wi y)." <i>J Inter</i>	th Risk on Med.		
				-			$\overline{}$				
								· · ·			
XAMINER		/D	avid Venci/		DATE CONSIDERED	01/2	2/2007	+			
xaminer: I	nitial if c	itation considered, of	whether or not citation with next communic	n is in conforman	ce with MPEP 609; Dra	w line throug	h citation if not	in conform	ace and		

<b>\</b> '	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. Not Yet Assigned
INFORMATI	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
Us	se several sheets if necessary)	FILING DATE Filed Concurrently herewith	GROUP Not Wet Assigned

### **U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	U.S. Patent Document Number	Date	. Name	Class	Subclass	Filing Date If Appropriate
		5,024,829	<b>X</b> 1991	Berger et al.			
		5,026,537	6/1991	Daddona et al.			
		5,046,499	9/1991	Berger			·
		5,120,834	6/1992	Gargan et al.			
		5,196,324	3/1993	Bumol et al.			
		5,223,410	6/1993	Cargan et al.			
		5,362,649	11/1994	Schwertner			
		5,380,667	1/1995	Schwertner			
		5,396,886	3/1995	Cuypers			
		5,453,359	9/1995	Gargan et al.			
		5,487,892	1/1996	Gaggan			
		5,597,726	1/1997	Bumol et al.			
		5,604,105	2/1997	Jackowski			·
		5,658,729	8/1997	Hayden et al.			
		5,690,103	11/1997	Groth et al.			
		5,710,008	1/1/998	Jackowski			
		5,731,208	3/1998	Henicke			
		5,756,067	5/1998	Redgrave et al.			
		6,040,147	3/2000	Ridker et al.			
,		6,309,888	10/2001	Holvoet			
		2003/0100486	5/2003	Ridker			
		2003/0152566	8/2003	Schonbeck et al.			
		, <u> </u>					

EXAMINER

/David Venci/

DATE CONSIDERED

01/22/200

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RS1129593

•							SHE	ET 2 OF 1	
Form PTO-1449 (Rev. )			OF COMMERCE EMARK OFFICE					• /	
INFORM	MATION DISCLO BY APPLI		EMENT	APPLICANT Harold M. Bates					
	Use several sheets	if necessary)		FILING DATE Filed Concurrent	GROUI				
		FOI	REIGN PATEN	r documents		/			
	Document Number	Date		Country	Class	Subclass	Trans	lation	
	EP 0 327 418 A1	8/1989	ЕРО				Yes	No	
	EP 0 433 088 B1	6/1397	EPO						
	EP 0 484 863 A1	5/1992	EPO			<del> </del>			
	WO 94/23302	10/1994	PCT						
	WO 98/59248	12/1998	PCT						
	WO 00/14548	3/2000	RCT						
	Kokai 8-304395	11/1996	JP				Х		
			1		<del></del>				

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-14 (Rev. )	49	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. NotYet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT Harold M. Bates	
	\	(Use several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Vet Assigned
<u> </u>		OTHER DOCUMENTS (Including A		Noyi et Assigned
		Adams JE, 3d, Bodor GS, Day Ladenson JH, Jaffe AS. "Ca High Specificity For Cardia 88(1): 101-106.	ardiac Troponin I./ A	Marker With
		American Biogenetic Science (1995).	es Inc. 1995 Annual R	eport. 24 pages
		American Biogenetic Sciences. Focus on Diagnostic Tests: A Technology Analysis. Updated Full Report. 33 pages. Paisley and Habermas, Inc. (June 3, 1996).		
		American Biogenetic Sciences, Inc., "Renal dialysis joint venture announced by American Biogenetic Sciences, Inc. and Gull Laboratories, Inc." News Release (9/26/96)		
·		American Biogenetic Sciences, Inc. Jesup & Lamont Securities Corporation, "New Buy Recommendation dated March 28, 1996" (12 pages.)		
·		Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. "Cardiac-Specific Troponin I Levels To Predict The Risk Of Mortality In Patients With Acute Coronary Syndromes." N. Eng. J. Med. 1996; 335(18): 1342-1349.		
		AtheroGenics, Inc. Printout of Web Site (WWW.ATHEROGENICS.COM). Home page and "Technology Platform" and "In The News" sections. 17 pages (printed June 8, 1998).		
		Aviram M, Maor I. "Phospholipase D-Modified Low Density Lipoprotein Is Taken Up By Macrophages At Increased Rate. A Possible Role For Phosphatidic Acid." J. Clin. Invest. 1993; 91: 1942-1952.		
		Berliner JA, Heinecke JW. "The Role Of Oxidized Lipoproteins In Atherogenesis," Free Radical Biology & Medicine 1996; 20(5): 707-727		
EXAMINER		/David Venci/	DATE CONSIDERED 01	/22/2007
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

orm PTO-1449 ATTY. DOCKET NO. U.S. DEPARTMENT OF COMMERCE SERIAL NO. PATENT AND TRADEMARK OFFICE Not Yet Assigned C015043/0174944 **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Harold M. Bates FILING DATE GROUB (Use several sheets if necessary) Filed Concurrently Herewith Not Net Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) "Direkt Evidence For A Boyd A. Gown AM, Wolfbauer G, Chait A. Protein Recognized By A Monoclonal Antibody Against Oxidatively Modified LDL In Atherosclerotic Lesions From A Watanabe Ayperlipidemic Rabbit." Am. J. Pathol. 1989 November; 135(5): 815-825. "Hunt For Heart Disease Tracks A New Suspect." Brody, JE. The New York Times. 3 pages (Jan. 6/2004). Brown MS, Goldstain JL. "Lipoprote in Metabolism In The Macrophage: Implications For Cholesterol Deposition In Atherosclerosis." Annu. Review Biochem. 1983; 52: 223-261. Cartier R, Dagenais F Hollmann C, Cambron H, Buluran J. "Chronic Exposure To Cyclosperin Affects Endothelial And Smooth Muscle Reactivity In The Rat Aorta." Ann. Thorac. Surg. 1994; 58: 789-794. Chapelle JP. "How Should We proceed When A Myocardial Infarction Is Suspected," Aca Clinica Belgica 1984; 39(6): 393-395. Chen CH, Nguyen HH / Weilbaecher Q, Luo S, Gotto Jr. AM, Henry PD. "Basic Fibroblast Growth Factor Reverses Atherosclerotic Impairment Of Human Coronary Angiogenesis-Like Responses In Vitro." Atherosclerosis 1995; 116: 261-268. Chin JH, Azhar S, Hoffman BB. "Inactivation Of Endothelial Derived Relaxing Factor By Oxidized Lipoproteins." J. Clin. Invest. 19\$2; 89: 10-18. Cockcrof DW, Gault MH. "Prediction of creatinine clearance from serum creatinine." Nephron 1976; 16: 31 41 Crist SJ, Dunn JM, Rose ML, Barbir M, Yacoub MF "Antiendothelial Antibodies After Heart Transplantation: The Agcelerating Factor In Transplant-Associated Corolary Artery Disease?" J. Heart Lung Transplant. 1994; 13(1, Part 1): 81-92. **EXAMINED DATE CONSIDERED** /David Venci/ 01/22/2007 Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-144 (Rev. )	9 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned	
INFO	DRMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates		
	(Use several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Jet Assigned	
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Declerck PJ, Mombaerts P, F "Fibrinolytic Response And Patients With Deep Vein Thr 58(4): 1024-1029.	Fibrin Fragment D Di	mer Levels In	
	Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C. "Mortality Risk Factors In Patients Treated By Chronic Hemodialysis." Nephron 1982: 31: 103-110.			
	Esterbauer H, Jungens G, Quehenberger Q, Koller E. "Autooxidation Of Human Low Density Lipoprotein: Loss Of Polyunsaturated Fatty Acids And Vitamin E And Generation Of Aldehydes." J. Lipid Res. 1987; 28: 495-509.			
	Farber HW, Barnett HF. "Differences In Prostaglandin Metabolism In Cultured Aprilo And Pulmonary Arterial Endothelial Cells Exposed to Acute And Chronic Hypoxia." Circ. Res. 1991; 68(5): 1416-1457.			
	Fogelman MA, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. "Malondialdehyde Alteration Of Low Density Lipoproteins Leads To Cholesteryl Ester Accumulation In Human Monocyte-Macrophages." Prod. Natl. Acad. Sci. USA 1980; 77(4): 2214-2218.			
·	Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. "Lipoxygenase Contributes To The Oxidation Of Lipids In Human Atherosclerotic Plaques." J. Clin. Invest. 1995; 96: 504-510.			
	Friedman JA, Dwyer JT. "Hyperhomocysteinemia As A Risk Factor For Cardiovascular Disease In Patients Undergoing Hemodialysis." Nutr. Rev. 1995; 53(7): 197-201			
	Galle J, Bengen J, Schollmeyer P, Wanner C. Oxidized Lipoprotein(A) Inhibits Endothelium-Dependent Dilation: Prevention By High Density Lipoprotein." Eur. J. Pharmacol. 1994; 265: 111-115.		ilation:	
	_/			
EXAMINER	/David Venci/	DATE CONSIDERED 0	01/22/200	
Examiner: Init not considered.	ial if citation considered, whether or not citation is in conforman- Include copy of this form with next communication to applican	ce with MPEP 609; Draw line through citat t.	tion if not in conformance and	

Form PTO-1449 SERIAL NO. U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. PATENT AND TRADEMARK OFFICE (Nev. ) Nd Yet Assigned C015043/0174944 **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Harold M. Bates (Use several sheets if necessary) **FILING DATE** GROUP Filed Concurrently Herewith Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, E.)

Other Docores (including Author, Title, Date, Pertinent Pages, Etc.)			
	Low Density Lipoproteins S	ce Of The Endothelium." Eur. Heart J.	
	Gerrity RG. "The Role Of The Monocyte In Atherogenesis. I. Transition Of Blood-Borne Monocytes Into Foam Cells In Fatty Lesions." Am. J. Pathol. 1981; 103(2): 181-190.		
	Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. "Cytomegalovirus Infection Is Associated With Cardiac Allograft Rejection And Atherosclerosis." J. Am. Med. Assoc. 1989; 261(24): 3561-3566.		
	Haberland MD, Fogelman AM, Edwards PA. "Specificity Of Receptor-Mediated Recognition Of Malondialdehyde-Modified Low Density Lipoproteins." Proc. Watl. Acad. Sci USA. 1982; 79: 1712-1716.		
	Haberland ME, Olch CL, Fogelman MM. "Role Of Lysines In Mediating Interaction Of Modified Low Density Lipoproteins With The Scavenger Receptor Of Human Monocyte Macrophages." J. Biol. Chem. 1984; 259(18): 11305-11311.		
	Hamm WC, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. "Emergency Room Triage Of Ratients With Acute Chest Pain By Means Of Rapid Testing For Cardiac Troponin T Or Troponin I." N. Eng. J. Med. 1997; 337(23): 1648-1653.		
	Hamm Wo, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. "Emergency Room Triage Of Patients With Acute Chest Pain By Means Of Rapid Testing For Cardiac Troponin T Or Troponin I." N. Eng. J. Med. 1997; 337(23): 1648-1653.  Letters concerning same and authors' reply, published in N. Eng. J. Med. 1998; 338(18): 1314-1315.		
EXAMINER	/David Venci/	DATE CONSIDERED 01/22/2007	

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.

# Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

FILING DATE

Harold M. Bates

**APPLICANT** 

ATTY. DOCKET NO.

C015043/0174944

Filed Concurrently Herewith

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Hammer A, Kager G, Dohr G, Rabl H, Ghassempur I, Jurgens G. "Generation, Characterization, And Histochemical Application Of Monoclonal Antibodies Selectively Recognizing Oxidatively Modified ApoB-Containing Serum Lipoproteins."  Arterioscier. Thromb. Vasc. Biol. 1995; 17(5): 704-713.		
	Hansson GK, Libby P. (eds.). Immune Functions of the Vessel Wall, Volume II (Harwood Academic Publishers 1996). Chapter 9: Witztum JL, Palinski W. "Autoimmunity To Oxidized Lipoproteins." Pages 159-171.		
	Havel RJ, Eder HA, Bragdon JH. "The Distribution And Chemical Composition Of Ultracentrifugally Separated Lipoproteins In Human Serum." J. Clin. Invest. 1955; 34: 1345-1353.		
	Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively Modified LDL Contains Phospholipids With Platelet-Activating Factor-Like Activity And Stimulates The Growth Of Smooth Muscle Cells."  J. Clin. Invest. 1995; 96: 1322-2330.		
	Hirschfield GM, Pepys MB. "C reactive protein and cardiovascular disease: new insights from an old molecule." Q J Med. 2003 Nov; 96(11): 793-807		
	Hlatky MA. "Evaluation Of Chest Pain In The Emergency Department." N. Eng. J. Med. 1997; 37(23): 1687-1689.		
	Hoff HF, O'Nell J. "Lesion-Derived Dow Density Lipoprotein And Oxidized Low Density Lipoprotein Share A Lability For Aggregation, Leading To Enhanced Macrophage Degradation." Arterioscler. Thromb. 1991; 11(5): 1209-1222.		
·	Hoff HF, O'Neill J, Chisolm III GM, Cole TB, Quehenberger O, Esterbauer H, Jurgens G. "Modification Of Low Density Lipoprotein With 4-Hydroxynonenal Induces Uptake By Macrophages." Arteriosclerosis 1989; 9(4): 538-549.		
EXAMINER /David Venci/		DATE CONSIDERED 01/22/2007	

Examiner Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. "Alterations Of Coagulation And Fibrinolytic And Kallikrein-Kinin Systems In The Acute And Post-Acute Phases In Patients With Unstable Angina Pectoris." Circulation 1995; 91(10): 2520-2527.		
	Holvoet P, Perez G, Bernar H, Brouwers E, Vanloo B, Rosseneu M, Collen D. "Stimulation With A Monoclonal Antibody (mAb4E4) Of Scavenger Receptor-Mediated Uptake Of Chemically Modified Low Density Lipoproteins By THP-1-Derived Macrophages Enhances Foam Cell Generation." J. Clin. Invest. 1994; 93: 89-98.		
	Holvoet P, Collen D "Bet To LDL Hypercholesterolemi Of Oxidized Lipoproteins A Coronary Atherosclerosis I Vasc. Biol. 1997; 17(11)	a Is Associated and A More Rapid in Rabbits." Art	With Higher Levels Progression Of
	Holvoet P, Collen D. "Oxidized Lipoproteins In Atherosclerosis And Thrombosis." FASEB J. 1994; 8: 1279-1284.		
	Holvoet P, Collen D. "Thrombosis And Atherosclerosis." Curr. Opinion Lipidol. 1997; 8: 320-328.		
	Holvoet P, Perez O, Zhao Z "Malondialdehyde Modified With Atherosclerotic Disea 2611-2619.	Low Density Lipo	proteins In Patients
·	Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Zesaffre E, Vanrenterghem Y, Collen D. "Correlation Between Oxidized Low Density Lipoproteins and Von Willebrand Factor In Chronic Renal Failure." Thromb. Naemost. 1996; 76(5): 663-669.		
	Holvoet P, Van Kleemput J, Collen D, Vanhaecke J. "Correlation Between Oxidized Low Density Lipoproteins And Coronary Artery Disease In Heart Transplant Patients." Abstract published in Final Programme of 66th Congress of the European Atherosclerosis Society, Florence (Italy), July 13-14, 1996; Abstract Book, page 47.		
EXAMINER	/David Venci/	DATE CONSIDERED	01/22/2007

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and pot considered. Include copy of this form with next communication to applicant.

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/David Venci/

**DATE CONSIDERED** 

01/22/2007

EXAMINE

•			SHEET 10 OF 18
Form PTO-1449 (Rev. )	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. Nd Yet Assigned
INFORM	IATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(Use several sheets if necessary)		FILING DATE Filed Concurrently Herewith	GROUP Not et Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
	Hruban RH, Beschorner WE, HH, Reitz BA, Hutchins GM. Heart Transplant Recipients Lymphocyte-Mediated Endother 137(4): 871-882.	"Accelerated Arterions Is Associated With	sclerosis In A T-
	Hulthe J, Fagerberg B. "Crassociated with subclinical inflammatory cytokines (AIR Biol. 2002 Jul 1; 22(7):116	l atherosclerosis dev R Study)." Arteriosc	elopment and
	Itabe H, Takeshima E, Iwasa	aki H. Kimura J. Yosh	ida Y, Imanaka

T, Takano T. "A Monoclonal Antibody Against Oxidized

Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H,

Vercellotti GM. Ferritin Protects Endothelial Cells From Oxidized Low Density Lipoprotein In Vitro." Am. J. Pathol.

Vasoconstriction Caused By Short-Term Cholesterol Feeding Is Corrected By Thromboxane Antagonist Or Probucol." J. Clin.

"A New Generation Of Tests To Determine Heart

DATE CONSIDERED

Oxidatively Modified Low Density Lipoprotein Using A Monoclonal Antibody." J. Lipid Res. 1996; 37: 45-53.

Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP.

New York Times News Service. 7 pages

Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS,

Kaplan R, Aynedjian HS, Schlondorff D, Bank N.

"Hyperlipidemia And Progressive Renal Disease X"

Exampler: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

Polypeptides."

Kolata, G.

Trouble."

not considered. Include copy of this form with next communication to applicant.

1995).

EXAMINER

1995; 147(3): 782-789.

Invest. 1/90; 86: 1707-1714.

1991, 39(Suppl.): S41-S48.

/David Venci/

Lipoprotein Recognizes Foam Colls In Atherosclerotic Lesions: Complex Formation Of Oxidized Phosphatidylcholines And

Kimura J, Sanaka T, Hata Y, Takano T. "Sensitive Detection Of

J. Biol. Chem. 1994; 269(21): 15274-15279.

"Renal

Kidney Int.

(Nov. 26,

01/22/2007

			SHEET 11 OF 18
Form PTO-1449 (Rev. )	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. NotYet Assigned
INFORMATIO	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(Us	e several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not You Assigned
	OTHER DOCUMENTS (Including Au	uthor, Title, Date, Pertinent Pages, Etc.	

	OTTEN DOCUMENT (including value), The, Bate, 1 criment rages, etc.)
	Koskinen P, Lemstrom K, Bruggeman C, Lautenschlager I, Hayry P. "Acute Cytomegalovirus Infection Induces K Subendothelial Inflammation (Endothelialitis) In The Allograft Vascular Wall. A Possible Linkage With Enhanced Allograft Arteriosclerosis."  Am. J. Pathol. 1994; 144(1): 41-50.
·	Kotani K, Maekawa M, Kanno T, Kondo A, Zoda N, Manabe M. "Distribution Of Immunoreactive Malondialdehyde-Modified Low-Density Lipoprotein In Human Serum." Biochimica et Biophysica Acta 1994; 1215. 121-125.
	Lee TH, Goldman L. "Serum Enzymes In The Diagnosis Of Acute Myocardial Infarction, Annals of Internal Medicine 1986; 105: 221-223.
	Libby P, Salomon RN, Payne DD, Schoen FJ, Pober JS. "Functions Of Vascular Wall Cells Related To Development Of Transplantation-Associated Coronary Arteriosclerosis." Transplant. Proc. 1989; 21(4): 3677-3684.
	Lynch SM, Morrow JD, Roberts II LJ, Frei B. "Formation Of Non-Cyclooxygenase-Derived Prostanoids (F2-Isoprostanes) In Plasma And Low Density Lipoprotein Exposed To Oxidative Stress In Vitro." J. Clip. Invest. 1994; 93: 998-1004.
	Mabile L, Fitoussi G, Periquet B, Schmitt A, Salvayre R, Negre-Salvayre A. "Alpha-Tocopherol And Trolox Block The Early Intracellular Events (TBARS And Calcium Rises) Elicited By Oxidized Low Density Lipoproteins In Cultured Endothelial Cells." Free Radic. Biol. Med. 1995; 19(2): 177-187.
	Major AS, Dove DE, Ishiguro H, Su YR, Brown AM, Liu L, Carter KJ, Linton MF, Fazio S. "Increased Cholesterol Efflux In Apolipoprotein AI (ApoAI)-Producing Macrophages As A Mechanism For Reduced Atherosclerosis In ApoAI((-/-)) mice."  Arterioscler Thromb Vasc Biol. 2001 Nov; 21(11) 1790-1795.
	Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, Jaross W. "Secretory Group II Phospholipase A2 In Human Atherosclerotic Plaques." Atherosclerosis 1995; 118: 173-181.
II /	

EXAMINER/ /David Venci/ 01/22/2007 DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and pot considered. Include copy of this form with next communication to applicant.

EXAMINER

/David Venci/

Arteriosclerosis 1990; 10(3): 325-335.

**DATE CONSIDERED** 

01/22/2007

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Oxidative Modification Of Low Density Lipoprotein."

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

336-349. "The Pathogenesia Of Atherosclerosis: A Perspective Ross R. Nature 1998; 362: 801-809. For The 1990s." Salonen JT, Yla-Herttyala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. "Autoantibody Against Oxidised LDL And Progression Of Carotid Atherosclerosis." / Lancet 1992; 3\( 9 \) (8798): 883-887. "Predicting Coronary Artery Disease. New Markers Sasavage N. Could Identify Patients At Risk." Clan. Lab. News March 1998; pages 6-7. Savenkova ML, Mueller DM, Heinecke JW. Tyrosyl Radical Generated By Myeloperoxidase Is A Physiological Catalyst For The Initation Of Lipid Peroxidation In Low Density Lipoprotein." J. Biol. Chem. 1994; 269(32): 20394-20400. Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzaga K, Beeson JH, Glagov S, Wissler RW. "Arterial Foam Cells With Distinctive Immunomorphologic And Histochemical Peatures Of Macrophages." Am. J. Pathol. 1980; 100(1): 57-80.

**EXAMINER** /David Venci/ DATE CONSIDERED 01/22/2007

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

#### Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. ) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT **BY APPLICANT** 

(Use several sheets if necessary)

ATTY. DOCKET NO.

C015043/0174944

**APPLICANT** 

Harold M. Bates

**FILING DATE** 

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	Current Concepts." J. Am. 3052.	Med. Assoc. 1990; 264 (23): 3047-	
	Sparrow CP, Partharasathy S, Leake DS, Steinberg D. "Enzymatic Modification Of Low Density Lipoprotein By Purified Lipoxygenase Plus Phospholipase-A2 Mimic Cell-Mediated Oxidative Modification." J. Lipid Res. 1988; 29: 745-753.  Steinberg D, Witztum JL. "Lipoproteins And Atherogenesis:		
	Sparrow CP, Olszewski J. "Cellulai Oxidative Modification Of Low Density Lipoprotein Does Not Require Lipoxygenases." Proc. Nat. Acad. Sci. USA 1992; 89: 128-131.		
	Selwyn AP, Kinlay S, Libby P, Ganz P. "Atherogenic Lipids, Vascular Dysfunction, And Clinical Signs Of Ischemic Heart Disease." Circulation 1997; 95(1): 5-7.		
	Schulz T, Schiffl H, Scheithe R, Hrboticky N, Lorenz R. "Preserved Antioxidative Defense Of Lipoproteins In Renal Failure And During Hemodialysis." Am. J. Kidney Dis. 1995; 25(4): 564-571.		
	Shultz EK. "Clinical Interpretation Of Laboratory Procedures." Chapter 14 in Teitz, Fundamentals of Clinical Chemistry. Burtis CA, Ashwood ER (eds.). 4th edition 1996. W.B.Saunders Company. Pages 192-199.		
	Shacter E. Quantification And Significance Of Protein Oxidation In Biological Samples." Drug Metab Rev. 2000 Aug-Nov; 32(3-4): 307-26.		
	Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, Robbie L, Ganz P, Kinlay S, Libby P. "Oxidized Low-Density Lipoprotein Augments And 3-Hydroxy-3-Methylglataryl Coenzyme A Reductase Inhibitors Limit CD40 And CD401 Expression In Human Vascular Cells." Circulation 2002; 106(23): 2888-2893.		

Examiner Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

01/22/2007